Yazar "Baysal, Bulent" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Comparison of the GenoType® MTBC Molecular Genetic Assay with culture methods in the diagnosis of tuberculosis
    (Termedia Publishing House Ltd, 2014) Kurtoglu, Muhammet Guzel; Ozdemir, Mehmet; Kesli, Recep; Baysal, Bulent
    Introduction: Clinical samples from 433 patients pre-diagnosed with tuberculosis in Konya, Turkey, were investigated prospectively to compare the GenoType (R) MTBC test (GenoType (R) MTBC) with conventional gold standard culture methods. Material and methods: Lowenstein Jensen (LJ) and Mycobacteria Growth Indicator Tube (MGIT)-960 culture methods and GenoType (R) MTBC were performed together. Results: Mycobacterium tuberculosis (M. tuberculosis) detection rates were 16.2% by culture methods, 15.4% by GenoType (R) MTBC, and 6% by acid-fast bacilli microscopy. The LJ or MGIT-960 with GenoType (R) MTBC detected M. tuberculosis in 12 samples each that were negative according to the other culture method alone. Among 70 M. tuberculosis-positive samples, detection rates were 37% (26/70) by microscopy and 82.8% (58/70) by LJ and MGIT-960, but 95.7% (67/70) by GenoType (R) MTBC. Conclusions: GenoType (R) MTBC may be used as a beneficial adjunct test to culture methods for the detection of M. tuberculosis.
  • Küçük Resim Yok
    Öğe
    The Efficiency of Hepatitis C Virus Core Antigen Test in the Diagnosis of Hepatitis C Infection
    (Galenos Yayincilik, 2016) Demircili, Mehmet Emin; Ozdemir, Mehmet; Feyzioglu, Bahadir; Baysal, Bulent
    Objective: It was aimed to investigate diagnostic value of hepatitis C virus (HCV) core antigen test in patients with positive or negative anti-HCV assay by comparing with HCV ribonucleic acid (RNA) assay. Materials and Methods: Serum samples obtained from 189 patients who were admitted to Necmettin Erbakan University Meram Faculty of Medicine between December 2010 and February 2012, and HCV RNA assay were carried out for various reasons. Two mL of samples were stored under suitable conditions and anti-HCV, HCV core antigen and strip immunoblot assay [Commercial INNO LIA (TM) HCV Score (Innogenetics NV in Ghent, Belgium)] were performed. Genotyping was performed in the amplicons of the samples with positive HCV RNA test. Results: The diagnostic sensitivity specificity, negative predictive value and positive predictive value of HCV core antigen test were 96.2%, 100%, 97.3%, and 100%, respectively. Sixty-five serum samples were genotyped and their distribution were detected: Fifty-nine samples were genotype 1b, 2-genotype 1a/1b, 1-genotype 3a, 1-genotype 4, 1-genotype 2a/2c, and 1 was genotype 1a. Conclusion: It was concluded that HCV core antigen assay is highly specific, sensitive, reliable, reproducible, and easy to perform. It may be applied as a supplemental and confirmatory test in anti-HCV assays in the diagnosis of HCV.
  • Küçük Resim Yok
    Öğe
    INVESTIGATION OF PARVOVIRUS B19 SEROPREVALENCE IN VARIOUS AGE GROUPS IN CENTRAL ANATOLIA REGION, TURKEY
    (Ankara Microbiology Soc, 2010) Dagi, Hatice Turk; Ozdemir, Mehmet; Baykan, Mahmut; Baysal, Bulent
    Human parvovirus B19 is a small, non-enveloped, icosahedral symmetric, single-stranded DNA virus that can cause a number of diseases, notably erythema infectiosum in children and aplastic crisis in patients with chronic hemolytic disorders. There have been limited data on the epidemiological pattern of parvovirus B19 infection in Turkey. The objective of this study was to investigate the seroprevalence of parvovirus B19 in Konya province (Central Anatolia), Turkey. Parvovirus B19 IgG antibodies were investigated by a commercial ELISA kit (RIDASCREEN, R-Biopharm AG, Germany) in 631 adults (age range: 18-> 60 years) and 542 children (age range: 0-17 years). The overall prevalence of parvovirus B19 IgG antibodies was 28.9%. The rate of parvovirus B19 IgG positivity was 20.7% (112/542) in the 0-17 years age group and was 36% (227/631) in the adult population. No significant difference in seropositivity rates were detected in terms of sex in children and adult group (p>0.05 in both groups). The rates of parvovirus B19 IgG seropositivity were 15.8% in 0-4 years age group, 16% in 5-9 years, 24.2% in 10-14 years, 40.9% in 15-19 years, 34.7% in 20-29 years, 35.5% in 30-39 years, 32.2% in 40-49 years, 37.5% in 50-59 years and 53.8% in > 60 years age group. The seropositivity rates in 0-4 and 5-9 years age groups were lower than the other age groups and the difference was statistically significant (p < 0.05). To determine the prevalence of parvovirus B19 in different age groups in different geographical areas is necessary since this will provide important information about the epidemiology of such infections.
  • Küçük Resim Yok
    Öğe
    Screening blood donors by nucleic acid amplification technology in Turkey
    (E-Century Publishing Corp, 2017) Ozdemir, Mehmet; Tuzuner, Ugur; Feyzioglu, Bahadir; Baykan, Mahmut; Baysal, Bulent
    Volunteer blood donors are screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection by various immunoassay methods in Turkey. The risk of enzyme immunoassay (EIA) negative and positive nucleic acid amplification technology (NAT) samples is not clearly understood yet. The purpose of this study is to screen for such donors in Turkey by a commercially available multiplex NAT test. All donors were screened by EIA and then NAT was performed on pools of six blood sera. When NAT reactive pools were determined they resolved to test the single donation samples. Single donor positive NAT sera were discriminated by polymerase chain reaction (PCR)-based diagnostic assay (COBAS AmpliScreen, Roche, USA). Incompatible sample results with EIA and NAT were searched with additional serologic and confirmatory tests. A total of 3000 donors were screened and detected seronegative, 9 HBV NAT cases (0.3%) and 1 HCV (0.03%) and 1 HIV NAT case (0.03%) were detected positively. Follow-up these donors were showed that the HCV yield case was a window period and all HBV NAT yield cases were occult carriers. The use of NAT will detect occult HBV and reduce window period in HCV. The yield rate, especially in occult HBV, was higher than that in non-endemic countries like Europian countries. Therefore, for routine donor screening by NAT will be provided safer blood transfusion in Turkey cost-effectively.